Impact of Timing of Premedication on Mucosal Visibility During Endoscopy: A Randomized Controlled Trial
- 10 April 2026
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (6) , 1874-1882
Abstract
Background: Adequate gastric mucosal visibility (GMV) is essential for high quality upper gastrointestinal (GI) endoscopy. Simethicone and N‐acetylcysteine (NAC) are commonly used to improve mucosal visibility, but the optimal timing of administration remains uncertain. Objective: This double‐blinded randomized controlled trial (RCT) evaluated the optimal interval between premedication (simethicone + NAC) and endoscopy for achieving adequate GMV. Design: In this RCT, adults undergoing elective upper GI endoscopy were randomized to four groups: placebo (Group 1), premedication to endoscopy interval of 10–20 (Group 2), 21–30 (Group 3), or > 30 min (Group 4). GMV was scored in four gastric regions (antrum, distal body, proximal body, fundus) on a 4‐point scale (range 4–16). The primary outcome was adequate GMV (total score < 7). Secondary outcomes included median total GMV score, region‐wise mucosal visibility scores, lesion detection rate, and predictors of adequate GMV. Results: A total of 1200 adults were randomized to four groups. Adequate GMV was significantly more frequent in Groups 3 (64.7%) and 4 (66.7%) than in placebo (2.7%) or Group 2 (25.0%). Subgroup analysis within Group 4 demonstrated a declining trend after 50 min. ROC analysis suggested an optimal cut‐off of 25 min in predicting adequate GMV with area under the curve of 0.80. In region‐wise analysis, mean visibility scores were lowest in antrum and distal body. There was no significant difference in the detection of gastric lesions across study groups ( p = 0.913). No serious adverse events related to premedication were observed. Conclusion: Premedication with simethicone and NAC significantly improves GMV. The improvement becomes optimal at 20–30 min after ingestion and is consistently maintained up to 50 min. Trial Registration: ClinicalTrials.gov identifier: NCT06581783Keywords
This publication has 19 references indexed in Scilit:
- Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative – Update 2025Endoscopy, 2025
- CONSORT 2025 statement: updated guideline for reporting randomized trialsNature Medicine, 2025
- Pre-medication with simethicone and N-acetyl cysteine for improving mucosal visibility during upper gastrointestinal endoscopy: A randomized controlled trialIndian Journal of Gastroenterology, 2023
- Optimal timing of simethicone administration prior to upper endoscopy: A multicenter, single-blind, randomized controlled trialEndoscopy International Open, 2023
- Premedication with simethicone for improving the quality of gastric mucosal visualization: a double-blind randomized controlled trialEndoscopy International Open, 2022
- Simethicone and N-acetyl cysteine combination as premedication before esophagogastroduodenoscopy: Double-blind randomized controlled trialEndoscopy International Open, 2022
- Premedication with simethicone and N-acetylcysteine for improving mucosal visibility during upper gastrointestinal endoscopy in a Western populationEndoscopy International Open, 2021
- A prospective randomized controlled trial comparing simethicone, N-acetylcysteine, sodium bicarbonate and peppermint for visualization in upper gastrointestinal endoscopySurgical Endoscopy, 2020
- Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trialGastrointestinal Endoscopy, 2018
- Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trialGastrointestinal Endoscopy, 1998